Home » News » Excellion to offer multi cancer early detection in Nigeria
Excellion to offer multi cancer early detection in Nigeria
April 29, 2024
Excellion to offer multi cancer early detection in Nigeria with OncoSeek

Excellion (Nigeria) and OncoInv (The Netherlands) have joined forces to make multi cancer early detection available in Nigeria.  OncoSeek® is a patient-friendly product to detect cancer as it is on a blood sample and requires no biopsy or imaging equipment.

OncoSeek® is a revolution in cancer diagnosis

Blood samples are analysed on 7 Protein Tumour Markers (PTM). The resulting data is processed by cloud-based software using Artificial Intelligence and big data to analyse the resulting data sets. The algorithm is operated by OncoInv and is fully GDPR compliant. 

OncoSeek® covers the most common aggressive cancers and its specificity and sensitivity are considered better than traditional approaches in the realm of early detection and diagnosis. 

OncoSeek® has been developed by SeekIn (China, US). SeekIn has partnered with OncoInv to make its products available to as many countries as possible. To fulfil this ambition OncoInv offers the products at low cost. 

About Excellion

Excellion International Limited was incorporated in 2012. Currently located in OPIC Estate Isheri- North Lagos, Excellion is a pharmaceutical firm focusing on promotive health care products and services to vulnerable populations to enhance early detection, diagnostic and prevention of diseases. In partnership with OncoInv of the Netherlands, they are currently promoting OncoSeek® in Nigeria. Their mission is to be the leading provider of high-impact healthcare products, services, and technologies to vulnerable populations through the adaptation of innovation, research, ICT, and science to enhance access to healthcare products and services in Nigeria.

About OncoInv 

OncoInv is based in Houten, the Netherlands. The mission of OncoInv is to make multi-cancer early detection solutions available to as many people as possible, thus improving the outcome for patients and their families. OncoInv offers its products and services on a not-for-profit basis in Low- and Middle-Income countries to ensure high availability by minimizing the costs. OncoInv is a fully owned subsidiary of the non-profit foundation Inspire2Live. For more information, please continue your visit on our website.

About SeekIn 

SeekIn is a biotech company founded in early 2018 in Shenzhen, China, focusing on blood-based pan-cancer early detection utilizing -generation sequencing and artificial intelligence. Since founded, SeekIn has been committed to providing cutting-edge and cost-effective solutions for cancer early detection, postoperative recurrence monitoring, and treatment response evaluation. SeekIn also developed novel molecular tests for leukaemia patients. With its proprietary technical advances, SeekIn has launched several research and clinical studies in collaboration with top-tier hospitals. SeekIn envisions that by leading a new norm for cancer early detection the clinical outcome of mid-/late-stage cancer patients can be reversed, and the cancer mortality rate can be reduced by 15%. For more information about SeekIn’s cutting-edge technologies and products, visit www.seekincancer.com 

About Inspire2Live 

Inspire2Live is an international patient advocacy organisation operating on an international level. They are on a mission to inspire and empower patients, researchers and clinicians to work together to prevent, treat and eliminate cancer. “If we all believe that healthcare should be for the benefit of patients, then we should be part of the discussion and the decision process: When about us, not without us.” Inspire2Live achieve their goals by connecting stakeholders in the medical industrial complex and organising congresses and discovery networks. These connections have led to many initiatives which are transforming the way research and healthcare work to become more patient-centric. They operate globally in full respect of local considerations. For more information, please visit www.inspire2live.org 

More news